Abstract
Respiratory syncytial virus (RSV) is a virus that causes outbreaks of acute lower respiratory tract infections (LRTI) worldwide. The infections are associated with high rates of hospitalizations, which may lead to death, especially in older adults and young children. Due to the morbidity and mortality associated with RSV, pharmaceutical companies have dedicated research to create a vaccine since the 1960s. Despite setbacks after the failure of the first RSV vaccine, new developments in research have led to the approval of two new vaccines. Ensuring healthcare professionals and patients are well-informed about these vaccines is crucial for facilitating informed, collaborative clinical decision-making regarding their administration.
Recommended Citation
Zents M, Wagner E, Hoang M, Swiger C. Respiratory Syncytial Virus Vaccines for Adults. Transformative Medicine (T-Med). 2023; 2(4):108-112. doi: https://doi.org/10.54299/tmed/zgke1217.